TD Cowen analyst Dan Brennan lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $17 and keeps a Hold rating on the shares. The firm said Q4 results were pre-announced last month with revenue in line with consensus and 2025 guided below. HCT competitive dynamics and GeneSight trends will be key to watch. Additionally the company announced CEO Diaz will step down with COO Raha appointed CEO effective April 30.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Reports Strong Revenue Growth in 2024
- Hold Rating on Myriad Genetics Amid Leadership Transition and Adjusted Revenue Expectations
- Myriad Genetics Announces CEO Transition in 2025
- Myriad Genetics CEO Paul Diaz to depart, Sam Raha to succeed
- Myriad Genetics sees FY25 adjusted EPS 7c-11c, consensus 6c